Technology

Technology

INTH-454 is a novel synthetic small molecule which inhibits the growth and induces cell death in a broad range of tumor cells. Hereby, it acts particularly on cancer cells with a high proliferative potential by inhibiting DNA replication and causing DNA damage which ultimately results in the death of these cells.

INTH-454 strongly inhibits tumor growth in various mouse models of human cancers, e.g., strong anti-tumor activity has been shown for INTH-454 in representative mouse models of, e.g., prostate cancer, small cell lung cancer and gastric (stomach) tumors as displayed below.



Most potent effects have been observed in tumors/cell lines which display particularly high proliferative potential and in which a dysregulation of the G1/S cell cycle checkpoint can be identified.   

Inthera currently plans to enter INTH-454 into clinical development in 2022 with an initial focus for the treatment of patients with advanced stages of prostate cancer (CRPC), and also for patients with advanced small cell lung cancer (SCLC).